EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Irreversible myeloperoxidase inhibitor mitiperstat and mitiperstat metabolites display immunogenicity in humans

Lonnie I J MacDonald, Silvia Martinez-Rivera, Georgia Wells, Joshua Gardner, Paul Thomson, Carl Whatling, Erik Michaëlsson, Liam Farrell, Xiaoli Meng, Catherine J Betts, Dean J Naisbitt

Toxicological Sciences · 2026-11-02 · 209 (11)

DOI: 10.1093/toxsci/kfag140 ↗
AbstractBibliografische Angaben

Abstract

Abstract Myeloperoxidase (MPO) dysregulation contributes to cardiovascular disease, making MPO a promising therapeutic target. Mitiperstat, an irreversible 2-thioxanthine MPO inhibitor in clinical development, has been linked to delayed-onset maculopapular rash. This study investigated whether mitiperstat and its metabolites (M7, M9, M10, M12) activate human T-cells in vitro. De novo T-cell responses from healthy donors were assessed using a dendritic cell: T-cell co-culture assay, and T-cell clones (TCCs) were characterized for compound specificity, phenotype, function, and cross-reactivity. Proliferation was measured by [3H]-thymidine incorporation, and cytokine/cytolytic molecule release (IFN-γ, IL-5, IL-13, granzyme-B) by ELISpot. Twenty-nine predominantly CD4+ TCCs were specific to mitiperstat, while forty-seven CD4+ and CD8+ TCCs responded to its metabolites. All drug-specific TCCs proliferated dose-dependently and secreted a heterogeneous Th1/Th2 cytokine and cytolytic profile. CD4+ and CD8+ TCC activation was attenuated by MHC-class II and MHC-class I blockade, respectively. Despite the irreversible on-target pharmacology of mitiperstat, nearly all responsive TCCs were activated via direct pharmacological interactions with proliferation occurring with drug or respective metabolite in the presence of glutaraldehyde-fixed antigen-presenting cells. In contrast, one TCC was activated with drug-pulsed antigen-presenting cells. TCCs showed high specificity for their cognate compounds with no cross-reactivity. These findings demonstrate the intrinsic immunogenicity of mitiperstat and its metabolites and establish a framework for assessing and comparing T-cell reactivity of future MPO-targeting therapies.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →